Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSIP1 | O75475 | 1/20 | 0.50 |
| ▸ | PTGES2 | Q9H7Z7 | 14/20 | 0.45 |
| ▸ | APLNR | P35414 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4967722 | 0.87 | PTGES2 (0.49) | PSIP1PTGES2 | |
| SCHEMBL4965334 | 0.86 | PSIP1 (0.55) | PSIP1PTGES2 | |
| SCHEMBL4964464 | 0.72 | APLNR (0.42) | PTGES2APLNRPOLB | |
| SCHEMBL4968002 | 0.71 | PSEN1 (0.36) | POLB | |
| SCHEMBL4967995 | 0.71 | PSEN1 (0.36) | POLB | |
| SCHEMBL4967989 | 0.71 | PKM (0.34) | APLNRPOLB | |
| SCHEMBL12459797 | 0.70 | PSIP1 (0.77) | PSIP1GAASMN1; SMN2 | |
| SCHEMBL15672937 | 0.69 | PSIP1 (0.75) | PSIP1PTGES2POLBGAASMN1; SMN2 | |
| SCHEMBL3712510 | 0.68 | PSIP1 (1.00) | PSIP1POLBGAASMN1; SMN2 | |
| SCHEMBL22778265 | 0.68 | PSIP1 (0.72) | PSIP1GAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080171737-A1 | CYCLIC SULFONAMIDE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-07-17 | — | — | US | disclosed |
| WO-2008073956-A2 | CYCLIC SULFONAMIDE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171737-A1 | CYCLIC SULFONAMIDE DERIVATIVES AND METHODS OF THEIR USE | SLC6A4, SLC6A2, SLC6A3 | PSIP1 1605/4885PTGES2 1609/4885APLNR 3069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.